Eli Lilly and Company announced promising results for its next-generation weight-loss drug Thursday, with patients losing up to 20.1 percent of their body weight on eloralintide.
The once-weekly amylin analog injection could be an enticing alternative for people looking to reap the benefits of the most popular weight-loss drugs on the market without one of their least-favorable side effects.